Corporate Compliance & Transparency in the Pharmaceutical Sector

We would like to thank our partners and sponsors for supporting us and the whole event, our speakers and advisers for contributing with their knowledge, experience and strategies, and all delegates for finding the time to join us in Prague. We are delighted that you chose to attend the Corporate Compliance & Transparency in the Pharmaceutical Sector and we had the chance to meet you there and talk to you.

If you have any further questions or you are just eager to learn more about our upcoming events, do not hesitate to contact us. We would also appreciate your comments and suggestions that could help us improve our future conferences.

Pharmaceutical companies across Europe are facing a series of emerging legislation aiming to prevent corruption and increase transparency within the industry. Although not expecting dramatic changes in the way companies do their business when new regulatory requirements will be in effect, with the goals of establishing a sustainable trust, avoiding negative publicity and possible cases of corruption and bribery, the industry is embracing transparency as a benefit and opportunity to achieve these aims. In order to strengthen the dialogue between stakeholders in the compliance areas of key concern, Fleming Europe is providing a platform for these multi-stakeholder discussions at its Prague meeting on CORPORATE COMPLIANCE & TRANSPARENCY IN VARIOUS EUROPEAN REGIONS.

Reasons to attend

Understand the current legal environment by hearing insights from the EU
Commission representatives, Transparency International and industry experts
Make compliance a competitive advantage by reinforcing a zero-tolerance approach in your company culture
Integrate internal anti-corruption measures with the commercial strategies
Developing an effective compliance program
Gain insight into key elements in creating a successful Code of Conduct
Hear different perspectives on openness and transparency in the relationship between physicians and pharmaceutical industry
Exploit anti-corruption measures for the lucrative emerging markets
Take part in multi-stakeholder discussions on regional compliance legislations